Using patient-derived B cells, Kling-Select facilitates the rapid detection of new antibodies and preserved viral epitopes.

Sanofi and Kling Bio have entered into a partnership aimed at accelerating the discovery of neutralising antibodies. The ...

Kling Bio has announced a new collaboration and licence option agreement with Sanofi to accelerate the discovery of neutralising antibodies using its proprietary B cell platform, Kling-Select.

Dutch privately-held biotech Kling Bio today announced it has entered into a collaboration and license option agreement with French pharma major Sanofi for the discovery of antibodies and epitopes ...

Kymera Therapeutics is celebrating the signing of two partnerships, with Gilead Sciences taking an option on one molecular glue programme, as Sanofi buys into another. The agreement with Gilead ...